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Effect of perindopril/indapamide/amlodipine ﬁxed-dose combination
on peripheral and central hemodynamics and vascular wall stiffness
parameters in patients with uncontrolled hypertension
T.A. Netchessova, S.V. Charnyak, L.V. Yakubova. Republican Scientiﬁc Practical
Center Cardiology, Laboratory of Hypertension, Minsk, Belarus
Objective: To evaluate the effects of perindopril/indapamide/amlodipine ﬁxed-
dose combination (FDC) on peripheral and central blood pressure (BP) param-
eters: systolic and diastolic blood pressure (SBP, DBP), central systolic blood
pressure (CSBP), central pulse blood pressure (CPBP), augmentation index (AI),
and pulse wave velocity (PWV) in patients with uncontrolled arterial hypertension
(AH).
Scope and methods of study. FDC was administered to 796 patients with Stage
1–3 AH. Mean age was 57.1±10.5 years; 51% of patients were male, 49% were
female. Parameters, such as CSBP, CPBP, AI, PWV and vascular age, were eval-
uated using an applanation tonometer (SphygmoCor system, Australia) at base-
line and after 5 months of treatment.
Results: As a result of FDC administration and dynamic monitoring for 5
months, SBP and DBP levels decreased from 166.5±15.4/97.4±8.5 mm Hg to
130.3±9.2/80.3±4.5 mm Hg (p<0.001). Target levels of SBP and DBP were
achieved in 84.6% and 88.2% of all patients, respectively. Target levels were
achieved in 100% of patients with Stage 1 AH, in 90% of patients with Stage 2 AH,
and in 72% of patients with Stage 3 AH. CSBP levels decreased from 141.7±2.27
to 117.0±2.27 mm Hg (p<0.001), CPBP levels decreased from 51.2±1.9 to
39.4±1.8 mm Hg (p<0.001), AI decreased from 27.4±2.21 to 23.1±1.71%
(p<0.05), and PWV decreased from 10.3 to 7.1 m/sec (p<0.05). Target levels
of CSBP and CPBP were achieved in 86.7% and 90% of all patients, respectively.
Baseline vascular age was 62.3±2.7 years and showed a statistically signiﬁcant
decrease to 54.8±2.8 years after 5 months (p<0.05).
Conclusion: Triple ﬁxed-dose combination allows to achieve adequate control of
BP in the majority of patients with uncontrolled AH, provides statistically signiﬁ-
cant decrease of peripheral and central BP, has an effect on rigidity and elastic
properties of the arterial wall, and leads to a decreased risk of cardiovascular
complications.
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CHINA STudy of valsartan/amlodipine ﬁxed-dose combination-bAsed
long-Term blood pressUre management in HypertenSive Patients: a
one-year registry (CHINA STATUS III)
Y. Huo1, B.W. Zhang1, Z. Du2. 1Peking University First Hospital, Cardiology,
Beijing, China People’s Republic of; 2Novartis Pharmaceuticals (China),
Shanghai, China People’s Republic of. On behalf of CHINA STATUS III study
group
Background: In China, hypertension is identiﬁed as the second leading risk fac-
tor for cardiovascular (CV) diseases. Compared with monotherapy, ﬁxed-dose
combination (FDC) antihypertensive therapy has been proposed to offer improved
efﬁcacy and enhanced patient compliance. Nevertheless, data on the long-term
efﬁcacy and safety of FDC from real-world settings in China is limited.
Purpose: The present observational study evaluated long-term management of
hypertension in patients receiving treatment with valsartan/amlodipine ﬁxed-dose
combination (Val/Aml FDC) in real-world setting in China.
Methods: This was a prospective, observational, multicenter, real-world registry
study wherein patients with hypertension who had already received Val/Aml FDC
for at least 4 weeks before study enrollment were observed for 1 year. Investi-
gators recorded patient data every 3 months and for 5 times during the 1-year
follow-up period. Effectiveness was assessed as blood pressure (BP) control rate
(Ofﬁce BP control was deﬁned as average BP<140/90mmHg and <135/85mmHg
for Home BP) and average duration on treatment at the end of study. Safety
was monitored by incidence of adverse events (AEs) and serious adverse events
(SAEs).
Results: Overall, 985 patients were enrolled (mean±SD age: 60.3±11.5 years);
of these, 894 were included in the full analysis set who had at least one post-
baseline visit, 758 completed the study. At baseline, BP was controlled (<140/90
mmHg) in 64.3% of patients on Val/Aml FDC for at least 4 weeks before enroll-
ment. Ofﬁce BP control rates improved signiﬁcantly (P<0.0001) from baseline at
months 3, 6, 9, and 12 visits (Figure). Signiﬁcant reductions in SBP (P<0.0001)
were assessed from baseline at months 3 (3.15 mmHg), 6 (3.0 mmHg), and
9 (4.43 mm Hg). In addition, signiﬁcant improvements were observed in home
Summary of ofﬁce BP control rate
blood pressure control rate from baseline to months 3 (73.1%), 6 (74.7%), and 9
(77.3%). Adherence to treatment was high: 91% of patients at month 6 reported
that they never missed one dose, and 93.4% of patients at month 6 and 95.3%
of patients at study end (month 12) maintained their Val/Aml FDC treatment. AEs
were reported in 23.3% of patients. A majority of AEs was mild to moderate and
0.6% of patients discontinued Val/Aml FDC because of SAEs.
Conclusion: Val/Aml FDC provided long-term sustained BP control with good
tolerability and good long-term compliance in this 1-year, real-world registry study
in patients with hypertension from China.
Funding Acknowledgements: Sponsorship for this study and article processing
charge was funded by Novartis Pharmaceutical (China).
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Ramipril signiﬁcantly attenuates the development of non-alcoholic
steatohepatitis in hyperlipidaemic rabbits
M.C. Soares Sturzeneker, D. Bertolim Precoma, L. Noronha, M. Olandoski,
L. Uhlmann Wendling, G.E. Jacomel, A. Gama Palone. Pontiﬁcal Catholic
University of Parana, Center of Health and Biological Sciences, Curitiba, Brazil
Background/Introduction: Non-alcoholic fatty liver disease (NAFLD) is consid-
ered as the most frequent cause of chronic hepatic disease in adults. The renin–
angiotensin system has been correlated to the whole basic physiopathogenic
mechanism of NAFLD in experimental models. Systemic arterial hypertension
has been suggested to be associated with NAFLD in approximately 40% of the
cases, and NAFLD has been independently associated with an increased risk of
arterial hypertension in observational studies. Therefore, we can infer that treat-
ing arterial hypertension in NAFLD carriers will be often necessary and that the
potential beneﬁcial effects of the antihypertensive might, in this context, inﬂuence
the choice of the respective drug.
Purpose: Based on these ﬁndings, we conducted this study to evaluate the ef-
fects of the angiotensin-converting enzyme inhibitor ramipril, used preventively, in
NAFLD induced in rabbits fed hyperlipidaemic diet.
Methods: Twenty-nine rabbits were divided into three groups (normal, placebo,
and ramipril). The placebo and ramipril groups were fed a ration containing
0.925% cholesterol. The groups were orally administered 0.35 mg/kg/day of
ramipril, and an equivalent volume of vehicle was administered to the placebo
group. At the end of the 8th week, all rabbits underwent segmental hepatic resec-
tion and were euthanized. Blood samples were collected to determine glucose,
insulin, creatinine, total cholesterol, triglycerides, high-density lipoprotein choles-
terol, and aminotransferase levels at baseline and euthanasia. Haematoxylin and
eosin and Gomori trichrome-stained slides were analysed based on the histolog-
ical scoring system for NAFLD. Sudan III-stained slides were analysed by mor-
phometry and inducible nitric oxide synthase (iNOS) immunostained based on
Allred scoring system.
Results: When compared with placebo, ramipril signiﬁcantly diminished the de-
velopment of steatosis (p=0.032), lobular inﬂammation (p=0.006), hepatocellu-
lar ballooning (p=0.023), and ﬁbrosis (p=0.02). Based on NAFLD activity score,
ramipril signiﬁcantly reduced the development of non-alcoholic steatohepatitis
(p=0.003). The mean area of positivity estimated by morphometry of Sudan III-
stained slides in the placebo group was signiﬁcantly higher compared with ramipril
(p=0.049). The expression of iNOS in the placebo group was signiﬁcantly higher
compared with ramipril (p<0.001).
Conclusion(s): The preventive use of ramipril in rabbits fed hyperlipidaemic diet
attenuates the development of the whole NAFLD histopathological spectrum. Fur-
ther studies are required to consolidate the criteria to choose the most appropriate
drugs or therapeutic classes for the treatment of arterial hypertension in NAFLD
carriers.
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Effect of nebivolol on lipid and metabolic proﬁles in Korean patients
with hypertension: Result from BENEFIT-KOREA study
S.W. Kwon1, J.-Y. Do2, G.-R. Hong3, B.-K. Kim3, W.M. Hwang4, S.-H. Kim5,
J.-Y. Lee6, S.W. Park7, D.-H. Kim1. 1Inha University Hospital, Cardiology,
Incheon, Korea Republic of; 2Yeungnam University Medical Center, Cardiology,
Gyeongsan, Korea Republic of; 3Yonsei Cardiovascular Center, Cardiology,
Seoul, Korea Republic of; 4Konyang University hospital, Nephrology, Daejeon,
Korea Republic of; 5Boramae Hospital, Cardiology, Seoul, Korea Republic of;
6Kangbuk Samsung Hospital, Cardiology, Seoul, Korea Republic of; 7A.Menarini
Korea Ltd., Seoul, Korea Republic of. On behalf of BENEFIT-KOREA
Background: Unlike conventional beta blockers, several studies proposed the
beneﬁcial effect of nebivolol on lipid and metabolic proﬁles. However, there is no
data so far demonstrating the impact of this new generation beta blocker on lipid
and metabolic proﬁles especially in Asian population.
Method: From 3011 enrolled patients in BENEFIT-KOREA study (BEneﬁts after
24 weeks of NEbivolol administration For essential hypertensIon patients wiTh
various co-morbidities and treatment environments in KOREA), 754 patients who
undergone blood sampling during the study period were investigated. Baseline
lipid and metabolic parameters were compared to 12 week and/or 24 week pa-
rameters. Patients who had altered lipid lowering medication during the study
period were excluded from the analysis.
Result: Mean age of the cohort was 63.5±12.9 years old with male predomi-
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